Longitudinal FDG-PET studies on at-risk subjects
| Study | N | Decline | Baseline Clinical Characteristics* | FU | Method | |||
|---|---|---|---|---|---|---|---|---|
| Age (yr) | M | MMSE | Ed | |||||
| Chételat et al, 200310 | 17/7 | MCI to AD | 69.9 (6.7) | 47.1 | 27.2 (1.3) | NA | 18 | SPM |
| Anchisi et al, 200511 | 48/14 | aMCI to AD | 67.7 (8.3) | 50.7 | 27.7 (1.7) | 11.0 (4.7) | 12 | SPM |
| Arnaiz et al, 200112 | 20/11 | MCI to AD | 62.7 (8.5) | 60.0 | 26.9 (2.3) | 11.6 (2.1) | 36.8 | rCMRGlu |
| Mosconi et al, 200413 | 37/8 | aMCI to AD | 67.1 (7.7) | 45.9 | 28.0 (1.5) | 9.6 (4.7) | 12.0 | SPM |
| Drzezga et al, 200514 | 30/12 | MCI to AD | 70.4 (7.8) | 46.7 | 26.9 (1.9) | 11.6 (3.4) | 15 | NEUROSTAT |
| Silverman et al, 200315 | 128/82 | MCI to D | 66 | 49.1 | 24 (6.4) | NA | 34.8 | NA |
Note:—aMCI indicates amnestic MCI; N, number of patients analyzed/number of conversions; M, % of male subjects; Ed, years of education; FU, mean follow-up time in months; D, dementia; SPM, statistical parametric mapping; rCMRGlu, regional cerebral glucose metabolic rates; NEUROSTAT, neurological statistical image analysis software; NA, not available; FDG-PET, fluorodeoxyglucose–positron-emission tomography.
* Each cell was listed as mean value (SD).